Founded in 2022, NEOsphere Biotechnologies integrates world-class mass spectrometry with expert data analysis to systematically build comprehensive pipelines of novel degrader targets. The company supports partners across all stages of targeted protein degradation (TPD) drug discovery programs, enabling deeper insights and accelerating the development of next-generation therapeutic solutions.